 Visit the TF Network Sites · Institutional Investor Center · Individual Investor Center |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other Feb 20 Calls Today's Calls |
| Call Details | |||
| The Medicines Company Earnings Conference Call (Q4 2012) Scheduled to start Wed, Feb 20, 2013, 8:30 am Eastern -- this event is ongoing now--
| |||
| About The Medicines Co (NasdaqGS:MDCO) | |||
| The Medicines Company operates as a global pharmaceutical company with a focus on advancing the treatment of critical care patients. The company markets Angiomax for use in patients undergoing coronary angioplasty; and Cleviprex, an injectable emulsion for the reduction of blood pressure. Its developing products include Cangrelor, an antiplatelet agent, which is in phase III clinical trial for the prevention of platelet activation and aggregation; Oritavancin that is in phase III clinical trial acts as an antibiotic for the treatment of serious gram-positive bacterial infections, including ABSSSI; and Argatroban, a phase III and NDA filed direct thrombin inhibitor used as anticoagulant for prophylaxis or for the treatment of thrombosis. The Medicines Company’s developing products also include CU2010, which is in phase I clinical trial that acts as a serine protease inhibitor for the reduction of blood loss during surgery; and ApoA-I Milano, a phase I clinical trial product for the reversal of atherosclerotic plaque development and reduction of the risk of coronary events in patients with ACS. The company sells its products through sales representatives and managers. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey. | |||
More Info: | |||
